

Please type a plus sign (+) inside this box



Approved for use through 10/31/99. OMB 0651-0031

PTO/SB/08A (10-96)

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1-90-100

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/981,222
Filing Date	October 16, 2001
First Named Inventor	Meir S. Sacks
Group Art Unit	1651
Examiner Name	F. C. Prats
Attorney Docket Number	MSS 49400

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		4,758,553		Ogoshi	07-19-1988	
		4,722,606		Sircar et al.	09-20-1988	
		4,845,215		Shimada et al.	07-04-1989	
		4,853,373		Livingston	08-01-1989	
		4,880,783		Mentzer Jr. et al.	11-14-1989	
		4,931,431		Livingston	06-05-1990	
		4,945,083		Jansen Jr.	07-31-1990	
		4,985,241		Zimmerman et al.	01-15-1991	
		5,043,100		Chang et al.	08-27-1991	
		5,051,429		Pinter et al.	09-24-1991	
		5,091,432		Glasky	02-25-1992	
		5,328,914		Hocquaux et al.	07-12-1994	
		5,391,568		Chung	02-21-1995	

RECEIVED

APR 15 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		GB	1,042,475		Kyowa Hakko Kogyo Co., Ltd	09-14-1966		
		EP	0113162		Carter et al.	07-11-1984		
		EP	0416248		Vesta Medicines Limited	03-13-1991		
		WO	94/00132		Pierre Fabre Medicament	1-16-1994		
		GB	2,280,110		The Howard Foundation	1-25-1995		
		WO	98/00101		Industria E Comercio de Cosméticos Natura Ltda.	01-08-1998		
		WO	00/00212		Nutracorp Scientific, Inc.	01-06-2000		

Examiner Signature


Date Considered

4-30-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box



Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE +


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 101 (Rev. 10-1992)				Complete if Known				
				Application Number	09/981,222			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	October 16, 2001			
				First Named Inventor	Meir S. Sacks			
				Group Art Unit	1651			
				Examiner Name	F. C. Prats			
				Attorney Docket Number	MSS 49400			
Sheet	2	of	2					
U.S. PATENT DOCUMENTS								
Examiner Initials [*]	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number	Kind Code ² (if known)					
SEP		5,447,939		Glasky et al.	09-05-1995			
		5,508,031		Zimmerman et al.	04-16-1996			
		5,563,126		Allen et al.	10-08-1996			
		5,667,776		Zimmerman et al.	09-16-1997			
		5,702,697		Zimmerman et al.	12-30-1997			
		5,728,707		Wehrmann	03-17-1998			
		5,795,873		Allen	08-18-1998			
		5,801,184		Glasky et al.	09-01-1998			
		5,872,124		Koprowski et al.	02-16-1999			
		6,008,221		Smith et al.	12-28-1999			
✓		6,338,963		Glasky et al.	01-15-2002			
		Publication No. US 2002/0042390		Benowitz	04-11-2002			
FOREIGN PATENT DOCUMENTS								
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
Examiner Signature						Date Considered	4-30-03	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box ☒ Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/981,222
				Filing Date	October 16, 2001
				First Named Inventor	Meir S. Sacks
				Group Art Unit	1651
				Examiner Name	F. C. Prats
Sheet	1	of	5	Attorney Docket Number	MSS 49400


Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SEP		VAN DYKE, "Drugs Used in the Treatment of Gout", <i>In Modern Pharmacology</i> , Chapter 17.	
		NUGENT ET AL., "The Renal Excretion of Uric Acid in Patients with Gout and in Nongouty Subjects", <i>Journal of Clinical Investigations</i> , 1959, 38, 1890-98.	
		SEEGMILLER ET AL., "The Renal Excretion of Uric Acid in Gout", <i>Journal of Clinical Investigations</i> , 1962, 41/5, 1094-98.	
		WASLIEN ET AL., "Uric Acid Production of Men Fed Graded Amounts of Egg Protein and Yeast Uric Acid", <i>The American Journal of Clinical Nutrition</i> , September 1968, 21/9, 892-97.	
		CLIFFORD ET AL., "Effect of Oral Purines on Serum and Urinary Uric Acid of Normal, Hyperuricemic and Gouty Humans", <i>J. Nutr.</i> , 1976, 106, 428-34.	
		GRIEBSCH ET AL., "Effect of Ribomononucleotides Given Orally on Uric Acid Production in Man", <i>Adv. Exp. Med. Biol.</i> , 1974, 41, 443-49.	
		WASLIEN ET AL., "Uric Acid Levels in Men Fed Algae and Yeast as Protein Sources", <i>Journal of Food Science</i> , 1970, 35, 294-98.	
↓		AMES ET AL., "Uric Acid Provides an Antioxidant Defense in Humans Against Oxidant- and Radical-Caused Aging and Cancer: A Hypothesis", <i>Proc. Natl. Acad. Sci. USA</i> , November 1981, 78/11, 6858-62.	

Examiner Signature		Date Considered	4-30-03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box ☒ Approved for use through 10/31/99. OMB 0651-0031

PTO/SB/08B (10-96)

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/981,222
				Filing Date	October 16, 2001
				First Named Inventor	Meir S. Sacks
				Group Art Unit	1651
				Examiner Name	F. C. Prats
Sheet	2	of	5	Attorney Docket Number	MSS 49400

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SEP		AMES, "The Detection of Environmental Mutagens and Potential Carcinogens", <i>Cancer</i> , May 15, 1984, 53/10, 2034-40.	RECEIVED APR 15 2003 TECH CENTER 1600/2900
		GROOTVELD ET AL., "Measurement of Allantoin and Uric Acid in Human Body Fluids", <i>Biochem. J.</i> , 1987, 243, 803-08.	
		FREI ET AL., "Ascorbate is an Outstanding Antioxidant in Human Blood Plasma", <i>Proc. Natl. Acad. Sci. USA</i> , August 1989, 86/16, 6377-81.	
		HARPARKASH ET AL., "Action of Biologically-Relevant Oxidizing Species Upon Uric Acid: Identification of Uric Acid Oxidation Products", <i>Chem. Biol. Interactions</i> , 1990, 73, 235-47.	
		PEDEN ET AL., "Uric Acid is a Major Antioxidant in Human Nasal Airway Secretions", <i>Proc. Natl. Acad. Sci. USA</i> , October 1990, 87, 7638-42.	
		SARWAR ET AL., "Assessment of the Uricogenic Potential of Processed Foods Based on the Nature and Quantity of Dietary Purines", <i>Progress in Food and Nutrition Science</i> , 1991, 15, 159-81.	
		BRULE ET AL., "Changes in Serum and Urinary Uric Acid Levels in Normal Human Subjects Fed Purine-Rich Foods Containing Different Amounts of Adenine and Hypoxanthine", <i>Journal of the American College of Nutrition</i> , 1992, 11/3, 353-58.	
✓		BECKER, "Towards the Physiological Function of Uric Acid", <i>Free Radical Biology & Medicine</i> , 1993, 14, 615-31.	

Examiner Signature		Date Considered	4-30-03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box



Approved for use through 10/31/99. OMB 0651-0031

PTO/SB/08B (10-96)

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/981,222
				Filing Date	October 16, 2001
				First Named Inventor	Meir S. Sacks
				Group Art Unit	1651
				Examiner Name	F. C. Prats
Sheet	3	of	5	Attorney Docket Number	MSS 49400

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Ser		WAGNER ET AL., "The Oxidation of Blood Plasma and Low Density Lipoprotein Components by Chemically Generated Singlet Oxygen", <i>Journal of Biological Chemistry</i> , September 5, 1993, 268/25, 18502-06.	
		KUIPER ET AL., <i>J. Neurol. Sci.</i> , 1994, 121:46-49.	
		MOTCHNIK ET AL., "Measurement of Antioxidants in Human Blood Plasma", <i>Methods in Enzymology</i> , 1994, 234, 269-79.	
		YOUNGMAN ET AL., "Effects of a Peroxisomal Proliferator (PP) on Plasma and Tissue Levels of Coenzyme Q9 (CoQ), Other Antioxidants, and Oxidative Damage to DNA (oxo8dG): Evidence that PP's deplete antioxidants and increase oxidative damage to DNA", <i>Molecular Aspects of Medicine</i> , 1994, 15 Suppl., 131-141.	
		OGIHARA ET AL., "Plasma Copper and Antioxidant Status in Wilson's Disease", <i>Pediatr. Res.</i> , February 1995, 37/2, 219-26.	
		OGIHARA ET AL., "New Evidence for the Involvement of Oxygen Radicals in Triggering Neonatal Chronic Lung Disease", <i>Pediatr. Res.</i> , 1996, 39, 117-19.	
		SZABO, "Physiological and Pathophysiological Roles of Nitric Oxide in the Central Nervous System", <i>Brain Research Bulletin</i> , 1996, 41/3, 131-41.	

RECEIVED

APR 15 2003

TECH CENTER 1600/2900

Examiner Signature		Date Considered	4-30-03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box



Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/981,222
				Filing Date	October 16, 2001
				First Named Inventor	Meir S. Sacks
				Group Art Unit	1651
				Examiner Name	F. C. Prats
Sheet	4	of	5	Attorney Docket Number	MSS 49400

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SEP		HOOPER ET AL., "Prevention of Experimental Allergic Encephalomyelitis by Targeting Nitric Oxide and Peroxynitrite: Implications for the Treatment of Multiple Sclerosis", <i>Proc. Natl. Acad. Sci. USA</i> , March 1997, 94, 2528-33.	RECEIVED APR 15 2003 TECH CENTER 1600/2900
		MAXWELL ET AL., "Antioxidant Status in Patients with Uncomplicated Insulin-Dependent and Non-Insulin-Dependent Diabetes Mellitus", <i>European Journal of Clinical Investigations</i> , 1997, 27, 484-90.	
		RYAN ET AL., "The Total Antioxidant Capacity of Human Serum Measured Using Enhanced Chemiluminescence is Almost Completely Accounted for by Urate", <i>Ann. Clin. Biochem.</i> , 1997, 34, 688-89.	
		SCHROD ET AL., "Possible Role of Uric Acid as an Antioxidant in Premature Infants", <i>Biol. Neonate</i> , 1997, 72, 102-11.	
		VAN DYKE, "The possible role of peroxynitrite in Alzheimer's disease: a simple hypothesis that could be tested more thoroughly", <i>Medical Hypotheses</i> , May 1997, 48(5), 375-380.	
		HOOPER ET AL., "Uric Acid, a Natural Scavenger of Peroxynitrite, in Experimental Allergic Encephalomyelitis and Multiple Sclerosis", <i>Proc. Natl. Acad. Sci. USA</i> , January 1998, 95, 675-80.	
✓		OGIHARA ET AL., "Oxidation Products of Uric Acid and Ascorbic Acid in Preterm Infants with Chronic Lung Disease", <i>Biol. Neonate</i> , 1998, 73, 24-33.	

Examiner Signature		Date Considered	4-30-03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

† Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/981,222
--------------------	------------

Filing Date	October 16, 2001
-------------	------------------

First Named Inventor	Meir S. Sacks
----------------------	---------------

Group Art Unit | 1651

Examiner Name	F. C. Prats
---------------	-------------

Attorney Docket Number	MSS 49400
------------------------	-----------

Sheet

5

of


5

[illegible]

RECEIVED

APR 15 2003

TECH CENTER 1600/2900

Examiner Signature		Date Considered	4-30-03
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

† Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.